Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infection
Autor: | Richard H. Drew, Mary L. Townsend, V. Paul DiMondi |
---|---|
Rok vydání: | 2015 |
Předmět: |
Male
medicine.medical_specialty Time Factors Combination therapy Population Pharmaceutical Science Pharmacy Toxicology Tazobactam Cohort Studies Risk Factors Internal medicine medicine Humans Pseudomonas Infections Pharmacology (medical) Mortality education Aged Retrospective Studies Pharmacology education.field_of_study business.industry Odds ratio Middle Aged medicine.disease Anti-Bacterial Agents Surgery Pneumonia Treatment Outcome Bacteremia Pseudomonas aeruginosa Drug Therapy Combination Female business Body mass index Piperacillin medicine.drug |
Zdroj: | International Journal of Clinical Pharmacy. 37:348-354 |
ISSN: | 2210-7711 2210-7703 |
DOI: | 10.1007/s11096-015-0067-6 |
Popis: | Background Invasive infections with Pseudomonas aeruginosa (PA) are associated with significant morbidity and mortality. While risk factors for mortality have been identified, their influence on short-term outcomes impacting treatment selection has not been reported. Objectives The objective of this study was to evaluate the relationship between select patient- and treatment-related factors and short-term outcomes in patients with PA pneumonia and/or bacteremia. Setting Large academic medical center in the United States. Methods This IRB-approved single-center, retrospective case-cohort study included patients >18 years of age with culture-confirmed PA bacteremia and/or pneumonia receiving antimicrobial agent(s) active against PA. Main Outcome Measure Risk of unfavorable short-term treatment result. Results The population consisted of 117 patients (40 [34 %] and 77 [66 %] in the unfavorable and not-unfavorable groups, respectively). Baseline characteristics including age (mean of 63 years), gender (55 % male), Charlson score, creatinine clearance, and body mass index were comparable between groups. Piperacillin/tazobactam was the most common monotherapy antibiotic (46 and 33 % in unfavorable and not-unfavorable groups, respectively). Combination therapy primarily consisted of a beta-lactam plus ciprofloxacin in both unfavorable (10 %) and not-unfavorable (20 %) outcome groups. The preliminary regression model indicated that SIRS, direct ICU admission, and vasopressor therapy were associated with an unfavorable outcome. In addition, patients who received more than two active antimicrobials had a reduced risk of an unfavorable outcome. The final regression model revealed that vasopressor therapy (odds ratio [OR] 6.0; 95 % confidence interval [95 % CI] 2.3, 17) was associated with an unfavorable outcome, while receipt of greater than two active antibiotics was associated with a reduced risk of an unfavorable outcome (OR 0.26; 95 % CI 0.07, 0.83). Conclusions Treatment with more than two agents with activity against PA was associated with a reduced risk of an unfavorable short-term treatment outcome in patients with bacteremia and/or pneumonia. |
Databáze: | OpenAIRE |
Externí odkaz: |